SPONSOR
Debiopharm International SA
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 1
Conditions studied: Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade IIIHealthy Participants
Debiopharm International SA is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III, Healthy Participants.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Debiopharm International SA
How many clinical trials has Debiopharm International SA sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Debiopharm International SA, of which 2 are actively recruiting participants. These trials cover conditions including Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III, Healthy Participants. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Debiopharm International SA research focus on?
Debiopharm International SA clinical trials span Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III, Healthy Participants. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Debiopharm International SA clinical trial?
To participate in a Debiopharm International SA trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Debiopharm International SA trials with current recruitment status updated daily.
Clinical Trials by Debiopharm International SA
NCT05765812 Phase 1, Phase 2
Recruiting
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
NCT07035769 Phase 1
Recruiting
A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults
Healthy Participants
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology